Results for "vision impairment"
Cataracts
** A cataract is a progressive clouding of the eye’s natural lens that blurs vision, reduces quality of life, and remains the leading cause of global blindness. **CONTENT:** ## Overview A **cataract** is a cloudy or opacified area within the crystalline **lens** of the eye that interferes with the passage of light to the retina, producing a gradual decline in visual acuity. Most cataracts develop slowly over years and may affect one eye, both eyes, or alternate between them. Early symptoms often include **faded colours**, **blurry or double vision**, and **halos around lights**, especially at night. As the opacity progresses, patients may experience increased glare, difficulty reading, trouble recognizing faces, and a heightened risk of falls or depression due to reduced independence. The condition is primarily age‑related, but it can also arise from trauma, prolonged exposure to ultraviolet (UV) radiation, certain medications (e.g., corticosteroids), metabolic diseases such as diabetes, and genetic disorders. While cataracts are not painful, they can severely impair daily activities such as driving, reading, and navigating stairs. Prompt evaluation by an eye care professional is essential when vision changes suddenly, become markedly worse, or are accompanied by pain, redness, or flashes of light, as these may signal complications like **lens dislocation** or **secondary glaucoma**. ## History/Background The word “cataract” derives from the Greek *kataraktes*, meaning “waterfall,” reflecting the ancient belief that the condition caused a “waterfall” of fluid to obscure vision. Early descriptions appear in the writings of Hippocrates (5th century BC) and Galen, who noted cloudiness of the lens. The first successful extraction of a cataract—known as **couching**—was performed in ancient India around 600 BC, using a sharp instrument to displace the opaque lens into the vitreous cavity. This crude technique persisted for centuries until the 18th century, when French surgeon **J. J. Petit** introduced the **extracapsular cataract extraction (ECCE)** method, removing the lens while leaving the posterior capsule intact. A major breakthrough arrived in 1949 with **Sir Harold Ridley’s** invention of the **intra‑ocular lens (IOL)**, initially made from polymethyl methacrylate (PMMA). The first implantation in a human eye occurred in 1950, revolutionizing cataract surgery from a vision‑restoring procedure to a refractive one. Modern phacoemulsification, introduced by **Charles Kelman** in the 1960s, uses ultrasonic energy to emulsify the lens, allowing removal through a sub‑millimeter incision and rapid visual recovery. By the early 21st century, cataract surgery had become the most frequently performed elective operation worldwide. ## Key Information - **Epidemiology:** In 2020, cataracts accounted for **39.6 % of all blindness** and **28.3 % of visual impairment** globally, making them the single most common cause of blindness. Prevalence rises sharply after age 60, affecting up to 70 % of individuals in that age group. - **Risk Factors:** Age, diabetes, smoking, excessive UV exposure, long‑term steroid use, ocular trauma, and certain hereditary conditions (e.g., congenital cataracts). - **Types:** - *Nuclear sclerotic* (central lens hardening) – most common age‑related form. - *Cortical* (spokes radiating from the lens periphery) – associated with glare. - *Posterior subcapsular* (central posterior opacity) – often linked to steroid use and diabetes. - **Diagnosis:** Comprehensive eye exam with visual acuity testing, slit‑lamp biomicroscopy, and dilated fundus examination. Grading systems (e.g., LOCS III) quantify severity. - **Management:** Early stages may be monitored; visual aids (glasses, brighter lighting) can help. Definitive treatment is **cataract extraction** with IOL implantation. Modern phacoemulsification offers <10 minute surgery, <1 day postoperative recovery, and high success rates (>95 % achieving 20/40 vision or better). - **When to Seek Care:** Sudden vision loss, new pain, redness, flashes, or a marked increase in glare warrants immediate ophthalmologic evaluation to rule out complications such as **uveitis**, **retinal detachment**, or **acute angle‑closure glaucoma**. ## Significance Cataracts represent a major public health challenge because they disproportionately affect older adults, a demographic that is expanding worldwide due to increased life expectancy. The condition’s impact extends beyond visual loss; it contributes to reduced mobility, heightened fall risk, loss of independence, and mental health issues like depression. Economically, cataract‑related visual impairment imposes substantial costs on healthcare systems and societies through lost productivity and caregiving burdens. The evolution of cataract surgery—from ancient couching to modern micro‑incision phacoemulsification—exemplifies how technological innovation can transform a debilitating disease into a highly curable condition. Today, cataract surgery is not only a sight‑restoring procedure but also an opportunity for **refractive correction**, allowing patients to reduce dependence on glasses or contact lenses. Ongoing research into **laser‑assisted cataract surgery**, **premium IOLs** (e.g., multifocal, accommodating), and **pharmacologic cataract prevention** (e.g., lanosterol eye drops) promises to further enhance outcomes and accessibility, especially in low‑resource settings where cataract remains a leading cause of avoidable blindness. **INFOBOX:** - Name: Cataract (Lens Opacification) - Type: Ophthalmic disease / Vision disorder - Date: Predominantly age‑related; incidence rises after age 60 - Location: Crystalline lens of the eye (intra‑ocular) - Known For: Being the leading global cause of blindness and the most common indication for elective eye surgery **TAGS:** cataract, eye health, vision impairment, ophthalmology, aging, intra‑ocular lens, cataract surgery, public health
Health & MedicineConditions Encyclopedia Entry 1780592884
** This encyclopedia entry is about **Mitochondrial Myopathies**, a group of rare genetic disorders affecting the mitochondria, the energy-producing structures within cells. **CONTENT:** ## Overview Mitochondrial Myopathies (MM) are a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells. These disorders are characterized by the accumulation of mutations in the mitochondrial DNA, leading to impaired energy production and subsequent damage to various tissues, particularly muscles. Mitochondrial Myopathies are often inherited in an autosomal dominant pattern, meaning that a single copy of the mutated gene is enough to cause the condition. The symptoms of MM can vary widely, but often include muscle weakness, fatigue, and other systemic symptoms. Mitochondrial Myopathies are a complex and heterogeneous group of disorders, with over 150 different mutations identified in the mitochondrial DNA. The most common forms of MM include Myoclonic Epilepsy with Ragged-Red Fibers (MERRF), Kearns-Sayre Syndrome (KSS), and Chronic Progressive External Ophthalmoplegia (CPEO). Each of these conditions has distinct clinical features and prognoses, but all share a common underlying pathophysiology related to mitochondrial dysfunction. ## History/Background The first reported cases of Mitochondrial Myopathies date back to the 1960s, when a group of researchers identified a unique pattern of muscle damage in patients with myoclonic epilepsy. However, it wasn't until the 1980s that the underlying genetic cause of these disorders was identified. The discovery of the mitochondrial DNA and its role in energy production paved the way for a deeper understanding of the pathophysiology of MM. Since then, numerous studies have shed light on the molecular mechanisms underlying these disorders, leading to the development of new diagnostic and therapeutic strategies. ## Key Information Mitochondrial Myopathies are characterized by a range of clinical features, including: * Muscle weakness and wasting * Fatigue and exercise intolerance * Ophthalmoplegia (weakness of the eye muscles) * Epilepsy and seizures * Hearing loss and vision impairment * Cardiac conduction defects * Endocrine abnormalities The diagnosis of MM typically involves a combination of clinical evaluation, laboratory tests, and genetic analysis. Muscle biopsy is a key diagnostic tool, as it allows for the visualization of ragged-red fibers, a hallmark of mitochondrial myopathies. Genetic testing can identify the specific mutation responsible for the condition, which can inform prognosis and treatment decisions. ## Significance Mitochondrial Myopathies are a significant public health concern, affecting an estimated 1 in 5,000 individuals worldwide. While the exact prevalence of MM is unknown, it is estimated that over 100,000 people in the United States alone are affected by these disorders. The impact of MM on individuals and families cannot be overstated, as these disorders often result in significant disability, reduced quality of life, and increased healthcare costs. ## INFOBOX: - **Name:** Mitochondrial Myopathies - **Type:** Genetic disorder - **Date:** 1960s (first reported cases) - **Location:** Global - **Known For:** Rare genetic disorders affecting mitochondrial energy production ## TAGS: Mitochondrial Myopathies, genetic disorders, mitochondrial DNA, muscle weakness, fatigue, epilepsy, ophthalmoplegia, hearing loss, vision impairment, cardiology, endocrinology, genetic testing, muscle biopsy, ragged-red fibers.
Health & MedicineConditions Encyclopedia Entry 1780992267
** This encyclopedia entry is about **Mitochondrial Myopathies**, a group of rare genetic disorders that affect the mitochondria, the energy-producing structures within cells, leading to muscle weakness and other systemic symptoms. ## Overview Mitochondrial Myopathies (MM) are a group of rare genetic disorders caused by mutations in the mitochondrial DNA (mtDNA). These disorders affect the mitochondria, the energy-producing structures within cells, leading to impaired energy production and subsequent damage to various tissues, particularly muscles. Mitochondrial myopathies are characterized by progressive muscle weakness, fatigue, and other systemic symptoms, which can significantly impact an individual's quality of life. The disorders are often inherited in an autosomal dominant or maternal pattern, meaning they can be passed down from a parent or inherited from a mother. Mitochondrial myopathies are a diverse group of disorders, with over 150 different mutations identified in the mitochondrial DNA. The most common forms of MM include **Myoclonus Epilepsy with Ragged-Red Fibers (MERRF)**, **Kearns-Sayre Syndrome (KSS)**, and **Chronic Progressive External Ophthalmoplegia (CPEO)**. Each of these disorders has distinct clinical features, but they all share a common underlying defect in mitochondrial energy production. ## History/Background The first reported cases of mitochondrial myopathies date back to the 1960s, when researchers began to describe a group of patients with progressive muscle weakness and other systemic symptoms. In the 1980s, the discovery of mitochondrial DNA mutations revolutionized the field of mitochondrial research, allowing scientists to identify the genetic basis of these disorders. Since then, numerous studies have shed light on the molecular mechanisms underlying mitochondrial myopathies, leading to a better understanding of these complex disorders. ## Key Information Mitochondrial myopathies are characterized by a range of clinical features, including: * Progressive muscle weakness and fatigue * Muscle wasting and atrophy * Ophthalmoplegia (weakness of the eye muscles) * Epilepsy and seizures * Hearing loss and vision impairment * Cardiac conduction defects * Endocrine disorders The diagnosis of mitochondrial myopathies typically involves a combination of clinical evaluation, laboratory tests, and genetic analysis. Muscle biopsy and mitochondrial DNA sequencing are essential tools in the diagnosis of these disorders. Treatment options for MM are limited, and management is often focused on symptom relief and supportive care. ## Significance Mitochondrial myopathies are a significant public health concern, affecting an estimated 1 in 5,000 individuals worldwide. These disorders have a profound impact on an individual's quality of life, causing significant disability and premature mortality. Research into mitochondrial myopathies has led to a greater understanding of the molecular mechanisms underlying these disorders, paving the way for the development of novel therapeutic strategies. INFOBOX: - **Name:** Mitochondrial Myopathies - **Type:** Rare genetic disorders - **Date:** First reported cases in the 1960s - **Location:** Global prevalence - **Known For:** Progressive muscle weakness and impaired energy production TAGS: Mitochondrial myopathies, rare genetic disorders, mitochondrial DNA, muscle weakness, fatigue, ophthalmoplegia, epilepsy, hearing loss, vision impairment, cardiac conduction defects, endocrine disorders, muscle biopsy, genetic analysis, treatment options, supportive care.